• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BD inks UAE insulin pen distro deal with Julphar

August 28, 2018 By Fink Densford

Becton Dickinson, Julphar

Pharmaceutical manufacturer Julphar said yesterday it inked a deal with BD (NYSE: BDX) to supply disposable insulin pens to the United Arab Emirates.

Through the deal, individuals will be able to purchase BD’s Vystra disposable pens featuring Julphar’s human insulin formulations, including its Jusline R, Jusline N and Jusline 30/70. The same system is slated to be available for future insulin analogues which are still under development, Julphar said.

The Vystra pens are small, disposable, lightweight plastic handheld devices with pre-filled insulin cartridges designed for insulin injection for individuals living with Diabetes, the company said.

The pens are currently in the final stages of approval, Julphar said, and are slated to be launched as soon as they receive clearance from the Ministry of Health.

“The global diabetes market is large and growing. Through our agreement with BD, we will be able to keep pace with the growth and further improve our position in this lucrative market placing us among the top three players in the world. Many people in the UAE are suffering from what, in some cases, is a preventable condition. As a global leader in the manufacture of insulin, Julphar has a responsibility to not only raise awareness of the risk factors but to provide affordable, effective solutions that help diabetes sufferers live healthy, normal lives. An insulin pen offers more accuracy, convenience and confidence to diabetes sufferers and we look forward to launching these high-tech devices here in the very near future,” Julphar GM Jerome Carle said in a press release.

Earlier this month, the U.S. Dept. of Homeland Security issued an advisory warning consumers that BD’s Alaris syringe pumps can be hacked via a vulnerability that gives a remote attacker unauthorized access to the device when it is connected to a terminal server.

Filed Under: Business/Financial News, Diabetes, Distribution, Drug-Device Combinations, Featured Tagged With: Becton Dickinson, julphar

IN CASE YOU MISSED IT

  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS